Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Bylicki, Olivier; Tomasini, Pascale; Gervais, Radj; Guisier, Florian; Monnet, Isabelle; Ricordel, Charles; Bigay-Gamé, L.; Geier, M.; Chouaïd, C.; Daniel, Catherine; Swalduz, Aurélie; Toffart, Anne‐Claire; Doubre, H.; Peloni, J.-M.; Moreau, Diane; Subtil, Fabien; Grellard, Jean‐Michel; Castera, Marie; Clarisse, Bénédicte; Martins-Lavinas, Pedro-Henrique.; Decroisette, C.; Greillier, L.

doi:10.1016/j.ejca.2023.01.014

Cited by 15 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 56 studies were deemed eligible for full‐text review. Eventually, 17 studies were in accordance with our inclusion criteria (Figure 1), including eight RCTs, 23–25,31–37 eight retrospective studies, 38–45 and one Non‐RCT 46 . Among them, the randomized controlled clinical trial IMpower150 data came from two literatures, the PFS data came from the literature with Martin Reck as the first author, and the OS data came from the literature with Naoyuki Nogami as the first author.…”

Section: Resultsmentioning

confidence: 99%

“…Eventually, 17 studies were in accordance with our inclusion criteria (Figure 1 ), including eight RCTs, 23 , 24 , 25 , 31 , 32 , 33 , 34 , 35 , 36 , 37 eight retrospective studies, 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 and one Non‐RCT. 46 Among them, the randomized controlled clinical trial IMpower150 data came from two literatures, the PFS data came from the literature with Martin Reck as the first author, and the OS data came from the literature with Naoyuki Nogami as the first author. The sample size ranged from 18 to 444 participants, and the total number of participants enrolled in the RCTs was 1132, the number of participants in the Non‐RCT and retrospective studies was 953.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

Wang

Zhou

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundNon‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)‐mutated who progressed on EGFR tyrosine‐kinase inhibitor (EGFR‐TKI) therapy have limited therapeutic options. There is still no consensus on the role of immune checkpoint inhibitors (ICIs) in NSCLC with EGFR mutations.MethodsWe did a network meta‐analysis (NMA) with a systematic literature search on PubMed, Embase, Web of Science, and The Cochrane Library. We included all phase II and III randomized controlled trials (RCTs), non‐randomized controlled trials (Non‐RCTs), and retrospective studies. Progression‐free survival (PFS) and overall survival (OS) were assessed through hazard ratios (HR). Objective response rate (ORR) and adverse events (AEs) were assessed through odds ratio (OR) and relative risk (RR), respectively. R software was used to compare the outcomes of different treatments by Bayesian NMA.FindingsWe identified 1835 published results and 17 studies were included ultimately. A total of 2085 patients were included and accepted the following six treatments: ICIs plus chemotherapy (ICIs+Chemo), chemotherapy (Chemo), ICIs monotherapy (ICIs), ICIs plus chemotherapy and antiangiogenic therapy (ICIs+Chemo+Antiangio), antiangiogenic therapy plus chemotherapy (Antiangio+Chemo), ICIs plus antiangiogenic therapy (ICIs+Antiangio). ICIs+Chemo+Antiangio was associated with longer PFS and OS, as well as higher ORR (surface under the cumulative ranking curve [SUCRA], 96%, 90%, 91%). ICIs conferred the safety profile in terms of any‐grade AEs, grade greater than or equal to 3 AEs and any grade leading to treatment discontinuation occurred AEs (SUCRA, 99%, 68%, 94%).InterpretationICIs+Chemo+Antiangio brings the greatest survival benefit in NSCLC patients with EGFR mutations who progressed on EGFR‐TKI therapy, even for whom with baseline brain metastases. Compared with chemotherapy, ICIs has a low incidence of AEs and a benefit in OS.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

Wang

Zhou

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…These numbers are in the range reported for clinical treatment of melanoma and small cell lung cancer. [ 47 , 48 , 49 , 50 ] Increasing the LN‐FFR has a strong effect on the high antigen patients, but less effect on medium antigen production.…”

Section: Resultsmentioning

confidence: 99%

Transport Barriers Influence the Activation of Anti‐Tumor Immunity: A Systems Biology Analysis

Nikmaneshi,

Baish,

Zhou

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Effective anti‐cancer immune responses require activation of one or more naïve T cells. If the correct naïve T cell encounters its cognate antigen presented by an antigen presenting cell, then the T cell can activate and proliferate. Here, mathematical modeling is used to explore the possibility that immune activation in lymph nodes is a rate‐limiting step in anti‐cancer immunity and can affect response rates to immune checkpoint therapy. The model provides a mechanistic framework for optimizing cancer immunotherapy and developing testable solutions to unleash anti‐tumor immune responses for more patients with cancer. The results show that antigen production rate and trafficking of naïve T cells into the lymph nodes are key parameters and that treatments designed to enhance tumor antigen production can improve immune checkpoint therapies. The model underscores the potential of radiation therapy in augmenting tumor immunogenicity and neoantigen production for improved ICB therapy, while emphasizing the need for careful consideration in cases where antigen levels are already sufficient to avoid compromising the immune response.

show abstract

“…Immunotherapy combined with chemotherapy elicited a higher ORR in patients with ROS1‐positive NSCLC compared with immunotherapy alone 117,118 . In addition, a phase II clinical trial of Atezolizumab (NCT04042558) showed that Atezolizumab with or without bevacizumab and the “platinum‐Pemetrexed” chemotherapy regimen are effective in NSCLC patients with metastatic EGFR mutation or ALK/ROS1 rearrangement after TKI failure 119 . This suggests that immunotherapy combined with chemotherapy is a potential treatment strategy for patients with ROS1‐positive NSCLC, especially those for whom TKI therapy has failed.…”

Section: Treatment Of Ros1‐mutant Tumorsmentioning

confidence: 99%

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Li,

Zhang,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance associated with ROS1 inhibitors remain unknown. In addition, next‐generation ROS1 inhibitors, which have the advantage of treating central nervous system metastases and alleviating endogenous drug resistance, are still in the clinical trial stage.MethodIn this study, we searched relevant articles reporting the mechanism and clinical application of ROS1 in recent years; systematically reviewed the biological mechanisms, diagnostic methods, and research progress on ROS1 inhibitors; and provided perspectives for the future of ROS1‐targeted therapy.ResultsROS1 is most expressed in malignant tumours. Only a few ROS1 kinase inhibitors are currently approved for use in NSCLC, the efficacy of other TKIs for NSCLC and other malignancies has not been ascertained. There is no effective standard treatment for adverse events or resistance to ROS1‐targeted therapy. Next‐generation TKIs appear capable of overcoming resistance and delaying central nervous system metastasis, but with a greater incidence of adverse effects.ConclusionsFurther research on next‐generation TKIs regarding the localization of ROS1 and its fusion partners, binding sites for targeted drugs, and coadministration with other drugs is required. The correlation between TKIs and chemotherapy or immunotherapy in clinical practice requires further study.

show abstract

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Cited by 15 publications

References 23 publications

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

Transport Barriers Influence the Activation of Anti‐Tumor Immunity: A Systems Biology Analysis

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Contact Info

Product

Resources

About